Eliem Therapeutics, Inc

Historical 13F Holders

Symbol
CLYM
CUSIP
28658R106
All holders as of
Q3 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Shares Held, Excluding Options
Total Filers

13D/G Filers

Each filer's latest filing for 28658R106 since 12/18/2024, largest first.

Filer % of Class Filed
RA Capital Management, L.P. 13D/A
33.0% 11/9/2026
Event 11/5/2026
FMR LLC 13G/A
15.0% 11/5/2026
Event 9/30/2026
Pontifax Management 4 G.P. (2015) Ltd. 13G
7.7% 9/18/2025
Event 6/27/2024
James E. Flynn 13G
5.3% 10/28/2026
Event 10/27/2026
BlackRock, Inc. 13G 5.0% 10/27/2026
Event 9/30/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (3)
AI Eti LLC 13D/A
0% 10/16/2025
Event 10/14/2025
BML Investment Partners, L.P. 13G/A
0% 2/13/2025
Event 12/31/2024
MPM BioImpact LLC 13G/A 0% 8/14/2026
Event 6/30/2026

13F Holders by Quarter

Period Filers Shares, Excl. Options Value, Excl. Options
2026 Q3 128 65.2 M $747M
2026 Q2 108 56.3 M $734M
2026 Q1 80 32.3 M $221M
2025 Q4 65 31.2 M $157M
2025 Q3 68 44.6 M $89.7M
2025 Q2 70 49.9 M $61.9M
2025 Q1 76 51.9 M $63.4M
2024 Q4 81 55.7 M $100M
2024 Q3 72 54.7 M $278M
2024 Q2 48 49.9 M $355M
2024 Q1 22 16.9 M $46.2M
2023 Q4 24 16.9 M $45.5M
2023 Q3 24 16.7 M $44.0M
2023 Q2 23 16.7 M $46.8M
2023 Q1 20 16.7 M $48.4M
2022 Q4 21 16.6 M $61.0M
2022 Q3 23 14.8 M $47.8M
2022 Q2 30 15.1 M $45.7M
2022 Q1 44 17.5 M $147M
2021 Q4 36 17.4 M $182M
2021 Q3 33 17.3 M $311M